Zinc-leuprolide complex: Preparation, physicochemical characterization and release behaviour from in situ forming implant

Journal of Peptide Science

Volumn 13, Issue 10, 2007, Pages 649-654

  Astaneh, Reyhaneh ^a   Nafissi Varcheh, Nastaran ^a   Erfan, Mohammad ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

In situ forming implant; Modification of release; Non linear regression; Zinc leuprolide complex

Indexed keywords

LEUPRORELIN; ZINC COMPLEX;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SYNTHESIS; IMPLANT; IN VITRO STUDY; INFRARED SPECTROSCOPY; NONLINEAR SYSTEM; PRIORITY JOURNAL; REGRESSION ANALYSIS; STRUCTURE ANALYSIS; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; DRUG IMPLANTS; LEUPROLIDE; MEMBRANES, ARTIFICIAL; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION; ZINC;

EID: 35348892077     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.894     Document Type: Article

References (43)

1. Briken P, Hill A, Berner W. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J. Clin. Psgchiatry 2003; 64: 890-897.
2. Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin. Pharmacother. 2004; 5: 447-457.
3. Sharifi R, Ratanawong C, Jung A, Wu Z, Browneller R, Lee M. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv. Drug Deliv. Rev. 1997; 2: 121-138.
4. Plosker GL, Brogden RN. Leuprorelin: a review of its pharmacology and therapeutic use in prostataic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994; 48(6): 930-967.
5. Miller JD, Anderson MG. Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata. Adv. Drug Deliv. Rev. 1997; 28: 139-155.
6. Casadesus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen RL, Smith MA. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2004; 3: 281-285.
7. Meethal SV, Smith MA, Bowen RI, Atwood CS. The gonadotropin connection in Alzheimer's disease. Endocrine 2005; 26: 317-326.
8. Lu MF, Lee D, Rao S. Percutaneous absorption enhancement of leuprolide. Pharm. Res. 1992; 9(120): 1575-1579.
9. Qiu Y, Johnson HW, Reiland TL, Lu MF. Sublingual absorption of leuprolide: comparison between human and animal models. Int. J. Pharm. 1999; 179: 27-30.
10. Okada H, Heya T, Ogawa Y, Shimamoto T. One - month release injectable microcapsules of a luteinzing hormone-releasing hormone agonist(leuprolide acetate) for treating experimental in rats. J. Pharmacol. Exp. Ther. 1988; 244(2): 744-750.
11. Okada H, Doken Y, Ogawa Y, Toguchi H. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm, Res. 1994; 11: 1143-1147.
12. Woo BH, Kostanski JW, Gebrekidan S, Dani BA, Thanoo BC, DeLuca PP. Preparation, characterization and in vivo evaluation of 120-day poly(D, L-lactide) leuprolide microspheres. J. Controlled Release 2001; 75: 307-315.
13. Woo BH, Na KH, Dani BA, Jiang G, Thanoo BC, DeLuca PP. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D, L -lactide) leuprolide microspheres. Pharm. Res. 2002; 19: 546-550.
14. Wright JC, Leonard ST, Stevenson CL, Beck JC, Chen G, Jao RM, Johnson PA, Leonard J, Skowronski RJ. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Controlled Release 2001; 75: 1-10.
15. Hatefi A, Amesden B. Biodegradable injectable in situ forming drug delivery systems. J. Controlled Release 2002; 80: 9-28.
16. Hallas-Maller K, Petersen K, Schlichtkrull J. Crystalline and amorphous insulin-zinc compounds with prolonged action. Science 1952; 116: 394-398.
17. Homan JDH, Overbeek GA, Neutelings JPJ, Booli CJ, Van der Vies J. Corticotrophin zin phosphate and hydroxide, long-acting aqueous preparations. Lancet 1954; 13: 541-543.
18. Gietz U, Arvinte T, Haner M, Aebi U, Merkle HP. Formulation of sustained release aqueous Zn-hirudin suspensions. Eur. J. Pharm. Sci. 2000; 11: 33-41.
19. Gietz U, Arvinte T, Mader E, Oroszlan P, Merkle HP. Sustained release of injectable zinc-recombinant hirudin suspensions: development and validation of in vitro release model. Eur. J. Pharm. Biopharm. 1998; 45: 259-264.
20. Brodbeck KJ, Pushpala SA, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm. Res. 1999a; 16: 1825-1829.
21. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 2004; 58: 445-455.
22. Dunn RL, Enghlish JP, Cowsar DR, Vanderbilt DP. Biodegradable in situ Forming Implants and Methods of Producing the Same, US Patent 4 938 763, 1990.
23. Dunn RL. The artigel drug delivery system. In Modified-Release Drug Delivery Technology, Vol. 126, Hndgraft J, Roberts M (eds.). Marcel Dekker: New York, 2003; 647-655.
24. Yewey GL, Ellen GD, Cox SM, Dunn RL. Delivery of proteins from controlled release injectable implant. In Protein Delivery: Physical Systems, Sanders LM, Hendern RW (eds.). Plenum press: New York, 1997; 93-117.
25. Eligard package insert (Eligard- Leuprolide acetate for injectable suspension), http://products.sanofi-aventis.us/eligard/eligard_30.html.
26. Ravivarapu HB, Moyer KL, Dunn RL. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int. J. Pharm. 2000; 194: 181-191.
27. Ravivarapu HB, Moyer KL, Dunn RL. Sustained suppression of pituitary - gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J. Pharm, Sci. 2000; 89: 732-741.
28. Ravivarapu HB, Moyer KL, Dunn RL. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS Pharm. Sci. 2000; 1(1): E1.
29. Astaneh R, Moghimi HR, Erfan M, Mobedi H. Formulation of an injectable implant for peptide delivery and mechanistic study of the effect of polymer molecular weight on its release behavior. Daru 2006; 14(3): 65-70.
30. Wang W. Instability, stabilization and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 1999; 185: 129-188.
31. Choi SH, Park TG. Hydrophoboic ion pair formulation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres. Int. J. Pharm. 2000; 203: 193-202,
32. Shameem M, Lee H, Deluka PP. A short - term (accelerated relese) approach to evaluate peptide release from PLGA depot formulations. AAPS Pharm. Sci. 1999; 1(3): Article 7. DOI: 10.1208/ps010307.
33. Adjei AL, Hsu L. Leuprolide and other LH-RH analogues. In Stability and Characterization of Protein and Peptide Drugs: Case Histories, Wang YJ, Pearlman R (eds.). Plenum Press: New York, 1993; 176-181.
34. Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int. J. Pharm. 2007; 328: 42-48.
35. Luan X, Bodmeier R. Influence of poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. J. Controlled Release 2006; 110: 266-272.
36. Ravivarapu HB, Burton k, Deluka PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur. J. Pharm, Biopharm, 2000; 50: 263-270.
37. Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly (lactide-co-glycolide) microparticles. Eur. J. Pharm, Biopharm. 2006; 63: 205-214.
38. Chandrashekar BL, Zhon M, Jarr EM, Dunn RL. Controlled Release Liquid Delivery Compositions with Low Initial Drug Burst, U.S.Patent 6 143314, 2000.
39. Slager J, Domb AJ. Hetero-sterocomplexes of D-poly(lactic acid) and the LHRH analoque leuprolide. Application in controlled release. Eur. J. Pharm. Biopharm. 2004; 58: 461-469.
40. Alcock R, Blair JA, O'Mahony DJ, Raoof A, Quirk AV. Modifying the release of leuprolide from spray dried OED microparticles. J. Controlled Release 2002; 82: 429-440.
41. von Hippel PH, Schleich T. In Structure and Stability of Biological Macromolecules, Timasheff SN, Fasman GD (eds.). Marcel Dekker: New York, 1969; 417-573.
42. Tanford C. Physical Chemistry of Macromolecules. John Wiley & Sons: New York, 1961.
43. Robinson DR, Jencks WP. The effect of concentrated salt solutions on the activity coefficient of acetyltetraglycine ethyl seter. J. Am. Chem. Soc. 1965; 87: 2470-2479.